NeuroBo Pharmaceuticals
NASDAQ: MTVACambridge, US · Founded 2014 · Delaware corporation · 2 known investors
Biotech
Founders & leadership
MH
Marshall H. WoodworthExecutive Officer
HH
Hyung Heon KimExecutive Officer, Director
PK
P. Kent HawrylukBoard of Directors Member
MM
Margaret McShaneExecutive Officer
CB
Charles BisgaierExecutive Officer
MS
Mina SoochExecutive Officer
DL
David LowenschussExecutive Officer
AZ
Amy Zaremba RabournDirector
SH
Stephen HaakensonBoard of Directors Member
DO
Daniela OniciuExecutive Officer
DG
D. Gordon StricklandDirector
JP
James P. TursiDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$10MraisedMay 2025 · 2 investors · BiotechnologyRule 506(b)
▶$10MraisedMay 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark A. GlickmanDirector
- Andrew KovenDirector
- Jason L. GrovesDirector
- Marshall H. WoodworthExecutive Officer
- D. Gordon StricklandDirector
- Michael SalsburyDirector
- James P. TursiDirector
- Hyung Heon KimExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $422.7K
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17MraisedJul 2024 · 2 investors · BiotechnologyRule 506(b)
▶$17MraisedJul 2024 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- D. Gordon StricklandDirector
- James P. TursiDirector
- Michael SalsburyDirector
- Jason L. GrovesDirector
- Mark A. GlickmanDirector
- Andrew KovenDirector
- Marshall H. WoodworthExecutive Officer
- Hyung Heon KimExecutive Officer, Director
- Offering amount
- $17M
- Amount sold
- $17M
- Sales commissions
- $489.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14MraisedOct 2021 · 12 investors · BiotechnologyRule 506(b)
▶$14MraisedOct 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jason GrovesDirector
- Akash BakshiExecutive Officer
- Hyung Heon KimDirector
- Na Yeon KimDirector
- Andrew I KovenDirector
- Douglas J. SwirskyDirector
- Richard J. KangExecutive Officer, Director
- Michael SalsburyDirector
- Offering amount
- $14M
- Amount sold
- $14M
- Sales commissions
- $1.1M
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedFeb 2021 · 10 investors · BiotechnologyRule 506(b)
▶$10MraisedFeb 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeong Gyun OhDirector
- Douglas SwirskyDirector
- Jason GrovesDirector
- Na Yeon KimDirector
- Nicola ShannonExecutive Officer
- Akash BakshiExecutive Officer, Director
- Richard J. KangExecutive Officer, Director
- Michael SalsburyDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $700K
- Placement agents
- H.C. Wainwright & Co., Inc.
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17MraisedJan 2021 · 34 investors · BiotechnologyRule 506(b)
▶$17MraisedJan 2021 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard J. KangExecutive Officer, Director
- Akash BakshiExecutive Officer, Director
- Andrew BartynskiExecutive Officer
- Nadja MannowetzExecutive Officer
- Douglas SwirskyDirector
- Na Yeon KimDirector
- Jason GrovesDirector
- Jeong Gyun OhDirector
- Michael SalsburyDirector
- Nicola ShannonExecutive Officer
- Offering amount
- $17M
- Amount sold
- $17M
- Finders' fees
- $64K
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.5MraisedMar 2017 · 26 investors · PharmaceuticalsRule 506(b)
▶$12.5MraisedMar 2017 · 26 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey MathiesenExecutive Officer
- P. Kent HawrylukDirector
- Andy SassineDirector
- Steve GullansDirector
- Lee S. GoldenExecutive Officer
- Mina SoochExecutive Officer, Director
- Charles BisgaierExecutive Officer, Director
- Pedro LichtingerDirector
- Kenneth KouskyDirector
- Seth RenoExecutive Officer
- Offering amount
- $12.5M
- Amount sold
- $12.5M
- Sales commissions
- $1M
- Placement agents
- Piper Jaffray & Co., LifeSci Capital LLC
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$10.6MraisedApr 2016 · 59 investors · BiotechnologyRule 506(b)
▶$10.6MraisedApr 2016 · 59 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey MathiesenExecutive Officer
- Mina SoochExecutive Officer, Director
- Charles BisgaierExecutive Officer, Director
- Daniela OniciuExecutive Officer
- Margaret McShaneExecutive Officer
- Seth RenoExecutive Officer
- Andy SassineDirector
- Steve GullansDirector
- David LowenschussExecutive Officer
- Pedro LichtingerDirector
- Kenneth KouskyDirector
- P. Kent HawrylukDirector
- Offering amount
- $14M
- Amount sold
- $10.6M
- Minimum investment
- $10K
- Proceeds to insiders
- $900K
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$5MraisedApr 2015 · 46 investors · BiotechnologyRule 506(b)
▶$5MraisedApr 2015 · 46 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth KouskyDirector
- David LowenschussExecutive Officer
- Daniela OniciuExecutive Officer
- Charles BisgaierExecutive Officer
- Mina SoochExecutive Officer
- P. Kent HawrylukDirector
- Margaret McShaneExecutive Officer
- Amy Zaremba RabournDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Minimum investment
- $10K
- Proceeds to insiders
- $686.9K
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.